+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Biomarkers Market by Biomarker Type, Technology, Cancer Type, Test Type, Application, End User - Global Forecast 2026-2032- Product Image
Cancer Biomarkers Market by Biomarker Type, Technology, Cancer Type, Test Type, Application, End User - Global Forecast 2026-2032- Product Image
Sale

Cancer Biomarkers Market by Biomarker Type, Technology, Cancer Type, Test Type, Application, End User - Global Forecast 2026-2032

  • Report

  • 183 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4858011
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cancer Biomarkers Market is projected to reach USD 38.13 Billion in 2026. It is expected to continue growing at a CAGR of 11.09%, reaching USD 72.41 Billion by 2032.

Cancer biomarkers are measurable biological signals that help detect malignancy, classify tumors, predict treatment response, monitor minimal residual disease, and identify relapse earlier than conventional methods. Demand is anchored in the global cancer burden: IARC’s GLOBOCAN 2022 estimated about 20 million new cancer cases and 9.7 million cancer deaths worldwide, underscoring the need for earlier diagnosis, precision oncology, and longitudinal disease monitoring.

The field is moving from single-analyte testing toward integrated genomic, proteomic, epigenetic, metabolomic, and immune-profile biomarkers. Clinically established examples such as EGFR, ALK, HER2, BRCA1/2, PD-L1, MSI-H/dMMR, NTRK, and circulating tumor DNA are shaping companion diagnostics, targeted therapies, immuno-oncology decisions, and value-based cancer care across solid tumors and hematologic malignancies.

Transformative Shifts in the Cancer Biomarkers Landscape

The cancer biomarkers landscape is being reshaped by next-generation sequencing, liquid biopsy, multiplex immunohistochemistry, digital pathology, and decentralized sample collection. FDA-cleared and FDA-approved comprehensive genomic profiling tests have accelerated clinical adoption by linking biomarker results to targeted therapies, tumor-agnostic indications, hereditary cancer risk assessment, and immuno-oncology decisions.

A second shift is the expansion of biomarkers beyond late-stage treatment selection. Screening, early detection, therapy monitoring, and recurrence surveillance are gaining investment as clinicians seek faster, less invasive, and more longitudinal insight into tumor biology. This shift is also increasing demand for standardized pre-analytical workflows, harmonized reporting, external quality assessment, and evidence demonstrating clinical utility in real-world oncology practice.

Cumulative Impact of Artificial Intelligence on Cancer Biomarkers

Artificial intelligence is amplifying cancer biomarker discovery by analyzing pathology images, radiology data, multi-omics datasets, and real-world clinical records at scale. Public resources such as The Cancer Genome Atlas, which profiled more than 20,000 primary cancer and matched normal samples across 33 cancer types, provide a foundation for algorithmic biomarker research and molecular subtype classification.

AI is also improving workflow efficiency in laboratories by supporting variant interpretation, image quantification, quality control, patient stratification, and trial matching. The strongest near-term opportunity is not replacing expert judgment but combining machine learning with validated assays, transparent evidence, bias monitoring, data governance, and regulated clinical decision support that can be audited in routine cancer care.

Key Regional Insights Across Cancer Biomarker Adoption

North America remains a leading region for cancer biomarkers due to high oncology R&D intensity, broad access to advanced diagnostics, active FDA pathways for companion diagnostics, and extensive clinical trial networks. The United States and Canada benefit from established molecular pathology capabilities, national cancer research infrastructure, and growing use of liquid biopsy and comprehensive genomic profiling in oncology care. Europe benefits from strong academic oncology centers, EMA-aligned precision medicine frameworks, the European Health Data Space agenda, and cross-border research initiatives, although reimbursement, laboratory accreditation, and data-governance variation still affect adoption across countries.

Asia-Pacific is the fastest-evolving opportunity as China, Japan, India, South Korea, and Australia expand genomic medicine, oncology screening, national cancer strategies, and local diagnostic manufacturing capacity. Japan and South Korea demonstrate strong regulated adoption of molecular oncology, while China and India are increasing sequencing capacity and cancer diagnostics access for large patient populations. Latin America is improving access through private oncology networks, reference laboratories, and national cancer programs in countries such as Brazil and Mexico, while affordability and uneven specialist access remain constraints. The Middle East is investing in genomic health strategies, cancer centers, and specialty care infrastructure, particularly across Gulf health systems. Africa is gradually building pathology, biobanking, molecular testing, and workforce capacity to address late-stage diagnosis and support equitable cancer biomarker implementation.

Key Group Insights for Cancer Biomarker Growth

Among regional groups, the G7 anchors high-value cancer biomarker innovation through mature regulatory agencies, research funding, advanced oncology reimbursement systems, and deep clinical trial infrastructure. The European Union supports harmonization through the In Vitro Diagnostic Regulation, cancer mission funding, cross-country data initiatives, and quality standards that create demand for validated assays and evidence-based clinical implementation. NATO countries, many of which overlap with advanced oncology economies, increasingly view resilient diagnostic supply chains, laboratory readiness, and health data security as part of broader medical preparedness.

BRICS countries represent scale, epidemiologic diversity, and cost-sensitive innovation, particularly as China and India expand sequencing capacity and Brazil, Russia, and South Africa seek broader oncology diagnostics access under differing health system constraints. ASEAN is advancing cancer diagnostics unevenly across member states, but rising private healthcare investment, medical tourism, and regional reference laboratory models are supporting biomarker testing in urban oncology centers. GCC countries are prioritizing genomics, specialty cancer care, and national precision medicine programs, creating opportunities for molecular testing, companion diagnostics, and AI-enabled oncology workflows within rapidly modernizing health systems.

Key Country Insights in Cancer Biomarkers

The United States leads in companion diagnostics, liquid biopsy adoption, oncology trials, clinical guideline integration, and payer debate over clinical utility. Canada supports precision oncology through provincial genomic testing programs and cancer agencies, while Mexico and Brazil are expanding access through public and private oncology networks but continue to face affordability, referral, and laboratory-capacity constraints. The United Kingdom leverages national health system genomics initiatives and centralized testing pathways, Germany and France maintain strong molecular oncology networks and reimbursement mechanisms, and Italy and Spain are scaling cancer biomarker testing through regional healthcare systems with growing emphasis on standardization and equitable access.

Russia has scientific capability and oncology expertise but faces access, reimbursement, and supply-chain constraints affecting advanced molecular diagnostics. China is rapidly building domestic biomarker platforms, sequencing capacity, and precision oncology programs, while India is growing high-volume molecular diagnostics supported by expanding oncology hospitals and cost-conscious test models. Japan leads in regulated precision medicine adoption, including national approaches to genomic profiling and companion diagnostics. Australia benefits from national genomics programs, strong clinical research networks, and guideline-supported cancer testing, while South Korea combines advanced digital health infrastructure, high screening participation for several cancers, and strong translational cancer research to support biomarker-enabled oncology care.

Actionable Recommendations for Cancer Biomarker Leaders

Industry leaders should prioritize analytically validated assays, clinically meaningful endpoints, and evidence packages that address regulator, oncologist, laboratory, pathologist, and payer requirements. Partnerships among diagnostic developers, therapy developers, hospitals, reference laboratories, and academic cancer centers are essential for generating real-world evidence, improving trial enrollment, and expanding patient access to guideline-recommended biomarker testing.

Organizations should also invest in interoperable data infrastructure, AI governance, biospecimen quality controls, external quality assessment, cybersecurity, and scalable reimbursement strategies. The most defensible positions will combine biomarker science, operational reliability, companion diagnostic expertise, regulatory readiness, and equitable access models across mature and emerging oncology markets.

Research Methodology

Research methodology is built from verified secondary research and evidence synthesis across public health, regulatory, scientific, and industry sources. Core references include WHO and IARC cancer statistics, FDA and EMA diagnostic and therapy guidance, NCI resources, peer-reviewed oncology literature, clinical trial registries, professional guideline publications, and publicly available regulatory documentation.

The methodology emphasizes triangulation across disease burden, regulatory approvals, biomarker utility, technology adoption, reimbursement signals, clinical guideline inclusion, laboratory capacity, and regional healthcare readiness. Insights exclude unsupported market claims and prioritize data-backed trends relevant to cancer biomarker strategy, commercialization, clinical implementation, and precision oncology adoption.

Conclusion

Cancer biomarkers are becoming central to precision oncology as healthcare systems shift from generalized cancer treatment toward molecularly guided prevention, diagnosis, therapy selection, and monitoring. The combination of validated assays, liquid biopsy, AI-enabled analytics, digital pathology, multi-omics profiling, and real-world evidence is expanding the clinical value of biomarker-driven cancer care.

Sustainable advancement will depend on clinical utility, reimbursement clarity, regulatory quality, laboratory standardization, data governance, and equitable access. Organizations that align scientific innovation with practical oncology workflows, evidence generation, and patient-centered implementation will be best positioned to lead the next phase of cancer biomarker adoption.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Cancer Biomarkers Market, by Biomarker Type
7.1. Cellular Biomarker
7.2. Genetic Biomarker
7.2.1. DNA Biomarker
7.2.2. Epigenetic Biomarker
7.2.3. RNA Biomarker
7.2.3.1. Long Non-Coding RNA
7.2.3.2. Messenger RNA
7.2.3.3. MicroRNA
7.3. Metabolic Biomarker
7.4. Protein Biomarker
8. Cancer Biomarkers Market, by Technology
8.1. Enzyme Linked Immunosorbent Assay
8.2. Flow Cytometry
8.3. Mass Spectrometry
8.4. Next Generation Sequencing
8.5. Polymerase Chain Reaction
9. Cancer Biomarkers Market, by Cancer Type
9.1. Breast Cancer
9.2. Colorectal Cancer
9.3. Lung Cancer
9.4. Ovarian Cancer
9.5. Prostate Cancer
10. Cancer Biomarkers Market, by Test Type
10.1. Liquid Biopsy
10.2. Tissue Biopsy
11. Cancer Biomarkers Market, by Application
11.1. Companion Diagnostics
11.2. Diagnostics
11.3. Monitoring
11.4. Predictive Testing
11.5. Prognostics
12. Cancer Biomarkers Market, by End User
12.1. Academic Research Institutes
12.2. Biotechnology Companies
12.3. Contract Research Organizations
12.4. Diagnostic Laboratories
12.5. Hospitals
12.6. Pharmaceutical Companies
13. Asia-Pacific Cancer Biomarkers Market
14. North America Cancer Biomarkers Market
15. Latin America Cancer Biomarkers Market
16. Europe Cancer Biomarkers Market
17. Middle East Cancer Biomarkers Market
18. Africa Cancer Biomarkers Market
19. ASEAN Cancer Biomarkers Market
20. GCC Cancer Biomarkers Market
21. European Union Cancer Biomarkers Market
22. BRICS Cancer Biomarkers Market
23. G7 Cancer Biomarkers Market
24. NATO Cancer Biomarkers Market
25. United States Cancer Biomarkers Market
26. Canada Cancer Biomarkers Market
27. Mexico Cancer Biomarkers Market
28. Brazil Cancer Biomarkers Market
29. United Kingdom Cancer Biomarkers Market
30. Germany Cancer Biomarkers Market
31. France Cancer Biomarkers Market
32. Russia Cancer Biomarkers Market
33. Italy Cancer Biomarkers Market
34. Spain Cancer Biomarkers Market
35. China Cancer Biomarkers Market
36. India Cancer Biomarkers Market
37. Japan Cancer Biomarkers Market
38. Australia Cancer Biomarkers Market
39. South Korea Cancer Biomarkers Market
40. Competitive Landscape
40.1. Market Concentration Analysis, 2025
40.1.1. Concentration Ratio (CR)
40.1.2. Herfindahl Hirschman Index (HHI)
40.2. Recent Developments & Impact Analysis, 2025
40.3. Product Portfolio Analysis, 2025
40.4. Benchmarking Analysis, 2025
41. Company Profiles
41.1. Abbott Laboratories
41.2. Agilent Technologies, Inc.
41.3. Amoy Diagnostics Co., Ltd.
41.4. Becton, Dickinson and Company
41.5. BGI Genomics Co., Ltd.
41.6. Bio-Rad Laboratories, Inc.
41.7. bioMérieux SA
41.8. Burning Rock Biotech Limited
41.9. Caris Life Sciences, Inc.
41.10. Danaher Corporation
41.11. Exact Sciences Corporation
41.12. F. Hoffmann-La Roche Ltd
41.13. Foundation Medicine, Inc.
41.14. GE HealthCare Technologies Inc.
41.15. Genomic Health, Inc.
41.16. Guardant Health, Inc.
41.17. Hologic, Inc.
41.18. HTG Molecular Diagnostics, Inc.
41.19. Illumina, Inc.
41.20. Invitae Corporation
41.21. Luminex Corporation
41.22. Menarini Silicon Biosystems S.p.A.
41.23. Myriad Genetics, Inc.
41.24. NanoString Technologies, Inc.
41.25. Natera, Inc.
41.26. NeoGenomics Laboratories, Inc.
41.27. Opko Health, Inc.
41.28. PerkinElmer, Inc.
41.29. QIAGEN N.V.
41.30. Quest Diagnostics Incorporated
41.31. Ribomed Biotechnologies, Inc.
41.32. Siemens Healthineers AG
41.33. SOPHiA GENETICS SA
41.34. Sysmex Corporation
41.35. Thermo Fisher Scientific Inc.
41.36. Veracyte, Inc.
List of Figures
FIGURE 1. GLOBAL CANCER BIOMARKERS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CANCER BIOMARKERS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL CANCER BIOMARKERS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL CANCER BIOMARKERS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CANCER BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL CANCER BIOMARKERS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 17. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
FIGURE 21. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 25. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. EUROPE CANCER BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. EUROPE CANCER BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. AFRICA CANCER BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. AFRICA CANCER BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. ASEAN CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. ASEAN CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. GCC CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. GCC CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. BRICS CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. BRICS CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. G7 CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. G7 CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. NATO CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. NATO CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. UNITED STATES CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. CANADA CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. MEXICO CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. BRAZIL CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. GERMANY CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. FRANCE CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. RUSSIA CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. ITALY CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. SPAIN CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. CHINA CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. INDIA CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. JAPAN CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CANCER BIOMARKERS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CANCER BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL CANCER BIOMARKERS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CELLULAR BIOMARKER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CELLULAR BIOMARKER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CELLULAR BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL GENETIC BIOMARKER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GENETIC BIOMARKER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GENETIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL DNA BIOMARKER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL DNA BIOMARKER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL DNA BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL EPIGENETIC BIOMARKER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL EPIGENETIC BIOMARKER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL EPIGENETIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL RNA BIOMARKER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL RNA BIOMARKER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL RNA BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL LONG NON-CODING RNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL LONG NON-CODING RNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL LONG NON-CODING RNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL MESSENGER RNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL MESSENGER RNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL MESSENGER RNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL MICRORNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL MICRORNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL MICRORNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL METABOLIC BIOMARKER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL METABOLIC BIOMARKER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL METABOLIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL PROTEIN BIOMARKER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL PROTEIN BIOMARKER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL PROTEIN BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL OVARIAN CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL OVARIAN CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL LIQUID BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL TISSUE BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL TISSUE BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL TISSUE BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL PREDICTIVE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL PREDICTIVE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL PREDICTIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL PROGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL PROGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL PROGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 122. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 123. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 125. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 126. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 127. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 128. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 129. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 130. NORTH AMERICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 133. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 134. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 135. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 136. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 137. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 138. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 139. LATIN AMERICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 140. EUROPE CANCER BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 141. EUROPE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 142. EUROPE CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 143. EUROPE CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 144. EUROPE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 145. EUROPE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 146. EUROPE CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 147. EUROPE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 148. EUROPE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 149. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 150. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 151. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 153. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 154. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 158. AFRICA CANCER BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 159. AFRICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 160. AFRICA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 161. AFRICA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 162. AFRICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 163. AFRICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 164. AFRICA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 165. AFRICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 166. AFRICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 167. ASEAN CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 168. ASEAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 169. ASEAN CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 170. ASEAN CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 171. ASEAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 172. ASEAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 173. ASEAN CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 174. ASEAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 175. ASEAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. GCC CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 177. GCC CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 178. GCC CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 179. GCC CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 180. GCC CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 181. GCC CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 182. GCC CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 183. GCC CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 184. GCC CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 194. BRICS CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 195. BRICS CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 196. BRICS CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 197. BRICS CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 198. BRICS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 199. BRICS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 200. BRICS CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 201. BRICS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 202. BRICS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 203. G7 CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 204. G7 CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 205. G7 CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 206. G7 CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 207. G7 CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 208. G7 CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 209. G7 CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 210. G7 CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 211. G7 CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 212. NATO CANCER BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 213. NATO CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 214. NATO CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 215. NATO CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 216. NATO CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 217. NATO CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 218. NATO CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 219. NATO CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 220. NATO CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 221. UNITED STATES CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 222. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 223. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 224. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 225. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 226. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 227. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 228. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 229. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 230. CANADA CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 231. CANADA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 232. CANADA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 233. CANADA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 234. CANADA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 235. CANADA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 236. CANADA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 237. CANADA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 238. CANADA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 239. MEXICO CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 240. MEXICO CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 241. MEXICO CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 242. MEXICO CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 243. MEXICO CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 244. MEXICO CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 245. MEXICO CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 246. MEXICO CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 247. MEXICO CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 248. BRAZIL CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 249. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 250. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 251. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 252. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 253. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 254. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 255. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 256. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 257. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 258. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 259. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 260. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 261. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 262. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 263. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 264. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 265. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 266. GERMANY CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 267. GERMANY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 268. GERMANY CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 269. GERMANY CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 270. GERMANY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 271. GERMANY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 272. GERMANY CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 273. GERMANY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 274. GERMANY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 275. FRANCE CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 276. FRANCE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 277. FRANCE CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 278. FRANCE CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 279. FRANCE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 280. FRANCE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 281. FRANCE CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 282. FRANCE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 283. FRANCE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 284. RUSSIA CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 285. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 286. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 287. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 288. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 289. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 290. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 291. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 292. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 293. ITALY CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 294. ITALY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 295. ITALY CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 296. ITALY CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 297. ITALY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 298. ITALY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 299. ITALY CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 300. ITALY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 301. ITALY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 302. SPAIN CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 303. SPAIN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 304. SPAIN CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 305. SPAIN CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 306. SPAIN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 307. SPAIN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 308. SPAIN CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 309. SPAIN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 310. SPAIN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 311. CHINA CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 312. CHINA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 313. CHINA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 314. CHINA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 315. CHINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 316. CHINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 317. CHINA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 318. CHINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 319. CHINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 320. INDIA CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 321. INDIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 322. INDIA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 323. INDIA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 324. INDIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 325. INDIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 326. INDIA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 327. INDIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 328. INDIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 329. JAPAN CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 330. JAPAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 331. JAPAN CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 332. JAPAN CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 333. JAPAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 334. JAPAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 335. JAPAN CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 336. JAPAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 337. JAPAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 338. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 339. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 340. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 341. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 342. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 343. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 344. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 345. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 346. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 347. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 348. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 349. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKER, 2018-2032 (USD MILLION)
TABLE 350. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY RNA BIOMARKER, 2018-2032 (USD MILLION)
TABLE 351. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 352. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
TABLE 353. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 354. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 355. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Cancer Biomarkers market report include:
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Amoy Diagnostics Co., Ltd.
  • Becton, Dickinson and Company
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Burning Rock Biotech Limited
  • Caris Life Sciences, Inc.
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Foundation Medicine, Inc.
  • GE HealthCare Technologies Inc.
  • Genomic Health, Inc.
  • Guardant Health, Inc.
  • Hologic, Inc.
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • Invitae Corporation
  • Luminex Corporation
  • Menarini Silicon Biosystems S.p.A.
  • Myriad Genetics, Inc.
  • NanoString Technologies, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories, Inc.
  • Opko Health, Inc.
  • PerkinElmer, Inc.
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Ribomed Biotechnologies, Inc.
  • Siemens Healthineers AG
  • SOPHiA GENETICS SA
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Veracyte, Inc.

Table Information

Report AttributeDetails
No. of Pages183
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 38.13 Billion
Forecasted Market Value ( USD ) by 2032 $ 72.41 Billion
Compound Annual Growth Rate11.0%
Regions CoveredGlobal
No. of Companies Mentioned37

Related Topics

Related Reports

Cancer Biomarkers Market by Profiling Technology, Cancer, Product, Application, End User, And Region - Global Forecast to 2032 - Product Image

Cancer Biomarkers Market by Profiling Technology, Cancer, Product, Application, End User, And Region - Global Forecast to 2032

  • Report
  • 468 Pages
  • Global
From
Cancer Biomarkers Market - Types, Applications and Technologies - Product Image

Cancer Biomarkers Market - Types, Applications and Technologies

  • Report
  • 326 Pages
  • Global
From
Cancer Biomarkers - Global Strategic Business Report - Product Image

Cancer Biomarkers - Global Strategic Business Report

  • Report
  • 474 Pages
  • Global
From
Cancer Biomarkers Market Report and Forecast 2025-2034 - Product Image

Cancer Biomarkers Market Report and Forecast 2025-2034

  • Report
  • 350 Pages
  • Global
From
Cancer Biomarker Market Report 2026 - Product Image

Cancer Biomarker Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.